Kamada Ltd (XTAE:KMDA)
₪ 24.91 (0%) Market Cap: 1.44 Bil Enterprise Value: 1.26 Bil PE Ratio: 21.76 PB Ratio: 1.77 GF Score: 87/100

Kamada Ltd Corporate Update Call Transcript

Dec 08, 2025 / 01:30PM GMT
Release Date Price: ₪21.8 (-5.22%)
Brian Ritchie
LifeSci Advisors LLC - Analyst

Greetings and welcome to Kamaa Corporate Update conference call. At this time, all participants are on a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone requires operator assistance during the conference, please press 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Brian Ritchie, managing director of Lifeci Advisors.

Thank you. Please go ahead.

Amir London
Kamada Ltd - Chief Executive Officer

Thank you. This is Brian Richie with Lifesty Advisors, and thank you all for participating in today's call. Joining me from Kamata are Amir London, Chief Executive Officer, and Jaime Orlev, Chief Financial Officer. Earlier today, Kamata issued a press release announcing the company's decision to discontinue its Phase 3 inhaled AAT Innovate clinical trial while providing an update on its financial projections, which are the subject of today's corporate update call.

If you have not

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot